metformin has been researched along with Blood Clot in 17 studies
Metformin: A biguanide hypoglycemic agent used in the treatment of non-insulin-dependent diabetes mellitus not responding to dietary modification. Metformin improves glycemic control by improving insulin sensitivity and decreasing intestinal absorption of glucose. (From Martindale, The Extra Pharmacopoeia, 30th ed, p289)
metformin : A member of the class of guanidines that is biguanide the carrying two methyl substituents at position 1.
| Excerpt | Relevance | Reference |
|---|---|---|
| " This study aimed to evaluate the effect of adding Vildagliptin versus Glimepiride to ongoing Metformin on the biomarkers of inflammation, thrombosis, and atherosclerosis in T2DM patients with symptomatic coronary artery disease (CAD)." | 9.34 | Comparative clinical study evaluating the effect of adding Vildagliptin versus Glimepiride to ongoing Metformin therapy on diabetic patients with symptomatic coronary artery disease. ( Kabel, M; Mostafa, T; Omran, G; Shokry, A; Werida, R, 2020) |
| "We plan to prospectively investigate the effects of dipeptidyl peptidase-4 inhibition with vildagliptin on a number of atherothrombotic markers and adipokines in patients with proven atherosclerosis and type 2 diabetes." | 9.16 | Effects of a vildagliptin/metformin combination on markers of atherosclerosis, thrombosis, and inflammation in diabetic patients with coronary artery disease. ( Fisman, EZ; Goldenberg, I; Klempfner, R; Leor, J; Tenenbaum, A, 2012) |
| " In this context, metformin has been shown to not only contribute to a better glycaemic control but also to induce some weight loss (especially in the visceral depot) which may contribute to the improvement of the features of the metabolic syndrome." | 8.82 | Potential contribution of metformin to the management of cardiovascular disease risk in patients with abdominal obesity, the metabolic syndrome and type 2 diabetes. ( Després, JP, 2003) |
| " Metformin has a certain effect on anti-thrombosis, but its role and mechanism in MM-induced thrombosis are still uncovered." | 8.12 | Metformin Inhibits Multiple Myeloma Serum-induced Endothelial Cell Thrombosis by Down-Regulating miR-532. ( Dai, X; De, Z; Gao, L; Hu, J; Li, G; Li, L; Xu, F; Zhang, Y, 2022) |
| "Recent studies have suggested that metformin may inhibit endothelialization following limus-eluting stent (LES) placement and may increase the risk of stent thrombosis." | 7.80 | Stent thrombosis is not increased following percutaneous coronary intervention in patients with non-insulin dependent diabetes mellitus taking metformin. ( Chen, F; Lipinski, MJ; Pendyala, LK; Torguson, R; Waksman, R, 2014) |
| "Metformin, a first-line therapy for type 2 diabetes, is the only drug demonstrated to reduce cardiovascular complications in diabetic patients." | 5.43 | Metformin Uniquely Prevents Thrombosis by Inhibiting Platelet Activation and mtDNA Release. ( Cao, Y; Gu, J; Huang, W; Ji, C; Lee, KH; Li, K; Lu, Y; Ma, L; Morris-Natschke, SL; Niu, H; Qin, C; Wei, Z; Wen, L; Xia, Q; Xin, G; Xing, Z; Yeh, JL; Zhang, R; Zheng, H, 2016) |
| " This study aimed to evaluate the effect of adding Vildagliptin versus Glimepiride to ongoing Metformin on the biomarkers of inflammation, thrombosis, and atherosclerosis in T2DM patients with symptomatic coronary artery disease (CAD)." | 5.34 | Comparative clinical study evaluating the effect of adding Vildagliptin versus Glimepiride to ongoing Metformin therapy on diabetic patients with symptomatic coronary artery disease. ( Kabel, M; Mostafa, T; Omran, G; Shokry, A; Werida, R, 2020) |
| "We plan to prospectively investigate the effects of dipeptidyl peptidase-4 inhibition with vildagliptin on a number of atherothrombotic markers and adipokines in patients with proven atherosclerosis and type 2 diabetes." | 5.16 | Effects of a vildagliptin/metformin combination on markers of atherosclerosis, thrombosis, and inflammation in diabetic patients with coronary artery disease. ( Fisman, EZ; Goldenberg, I; Klempfner, R; Leor, J; Tenenbaum, A, 2012) |
| " Metformin is a biguanide compound which is antihyperglycaemic, reduces insulin resistance and has cardioprotective effects on lipids, thrombosis and blood flow." | 4.82 | Beneficial effects of metformin on haemostasis and vascular function in man. ( Grant, PJ, 2003) |
| " In this context, metformin has been shown to not only contribute to a better glycaemic control but also to induce some weight loss (especially in the visceral depot) which may contribute to the improvement of the features of the metabolic syndrome." | 4.82 | Potential contribution of metformin to the management of cardiovascular disease risk in patients with abdominal obesity, the metabolic syndrome and type 2 diabetes. ( Després, JP, 2003) |
| " Metformin has a certain effect on anti-thrombosis, but its role and mechanism in MM-induced thrombosis are still uncovered." | 4.12 | Metformin Inhibits Multiple Myeloma Serum-induced Endothelial Cell Thrombosis by Down-Regulating miR-532. ( Dai, X; De, Z; Gao, L; Hu, J; Li, G; Li, L; Xu, F; Zhang, Y, 2022) |
| "Recent studies have suggested that metformin may inhibit endothelialization following limus-eluting stent (LES) placement and may increase the risk of stent thrombosis." | 3.80 | Stent thrombosis is not increased following percutaneous coronary intervention in patients with non-insulin dependent diabetes mellitus taking metformin. ( Chen, F; Lipinski, MJ; Pendyala, LK; Torguson, R; Waksman, R, 2014) |
| "Platelet thrombosis is the main pathogeny resulting in the low curability of ischemic stroke, a leading cause of mortality and disability worldwide." | 1.56 | Novel potent antiplatelet thrombotic agent derived from biguanide for ischemic stroke. ( Chen, Z; He, Y; Huang, W; Ji, C; Lee, KH; Li, S; Li, Y; Ming, Y; Morris-Natschke, SL; Niu, H; Wei, Z; Xin, G; Xing, Z; Yang, X; Yu, K; Zhang, B; Zhang, J; Zhang, X, 2020) |
| "Metformin, a first-line therapy for type 2 diabetes, is the only drug demonstrated to reduce cardiovascular complications in diabetic patients." | 1.43 | Metformin Uniquely Prevents Thrombosis by Inhibiting Platelet Activation and mtDNA Release. ( Cao, Y; Gu, J; Huang, W; Ji, C; Lee, KH; Li, K; Lu, Y; Ma, L; Morris-Natschke, SL; Niu, H; Qin, C; Wei, Z; Wen, L; Xia, Q; Xin, G; Xing, Z; Yeh, JL; Zhang, R; Zheng, H, 2016) |
| "Metformin pre-treatment also reduced endothelial cell damage in ferrous chloride induced thrombosis in carotid arteries." | 1.37 | Investigation of the potential effects of metformin on atherothrombotic risk factors in hyperlipidemic rats. ( Bhadada, SV; Dhamecha, PS; Ghatak, SB; Panchal, SJ, 2011) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 2 (11.76) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 3 (17.65) | 29.6817 |
| 2010's | 6 (35.29) | 24.3611 |
| 2020's | 6 (35.29) | 2.80 |
| Authors | Studies |
|---|---|
| Xin, G | 2 |
| Ming, Y | 1 |
| Ji, C | 2 |
| Wei, Z | 2 |
| Li, S | 1 |
| Morris-Natschke, SL | 2 |
| Zhang, X | 2 |
| Yu, K | 1 |
| Li, Y | 1 |
| Zhang, B | 1 |
| Zhang, J | 1 |
| Xing, Z | 2 |
| He, Y | 1 |
| Chen, Z | 1 |
| Yang, X | 1 |
| Niu, H | 2 |
| Lee, KH | 2 |
| Huang, W | 3 |
| Usman, A | 1 |
| Bliden, KP | 1 |
| Cho, A | 1 |
| Walia, N | 1 |
| Jerjian, C | 1 |
| Singh, A | 1 |
| Kundan, P | 1 |
| Duhan, S | 1 |
| Tantry, US | 1 |
| Gurbel, PA | 1 |
| Gao, L | 1 |
| Li, L | 1 |
| Hu, J | 1 |
| Li, G | 1 |
| Zhang, Y | 1 |
| Dai, X | 1 |
| De, Z | 1 |
| Xu, F | 1 |
| Wang, Y | 1 |
| Fu, M | 1 |
| Xiao, W | 1 |
| Zhao, Y | 1 |
| Yuan, P | 1 |
| Wu, W | 1 |
| Menendez, JA | 1 |
| Werida, R | 1 |
| Kabel, M | 1 |
| Omran, G | 1 |
| Shokry, A | 1 |
| Mostafa, T | 1 |
| Soberanes, S | 1 |
| Misharin, AV | 1 |
| Jairaman, A | 1 |
| Morales-Nebreda, L | 1 |
| McQuattie-Pimentel, AC | 1 |
| Cho, T | 1 |
| Hamanaka, RB | 1 |
| Meliton, AY | 1 |
| Reyfman, PA | 1 |
| Walter, JM | 1 |
| Chen, CI | 1 |
| Chi, M | 1 |
| Chiu, S | 1 |
| Gonzalez-Gonzalez, FJ | 1 |
| Antalek, M | 1 |
| Abdala-Valencia, H | 1 |
| Chiarella, SE | 1 |
| Sun, KA | 1 |
| Woods, PS | 1 |
| Ghio, AJ | 1 |
| Jain, M | 1 |
| Perlman, H | 1 |
| Ridge, KM | 1 |
| Morimoto, RI | 1 |
| Sznajder, JI | 1 |
| Balch, WE | 1 |
| Bhorade, SM | 1 |
| Bharat, A | 1 |
| Prakriya, M | 1 |
| Chandel, NS | 1 |
| Mutlu, GM | 1 |
| Budinger, GRS | 1 |
| Habib, A | 1 |
| Karmali, V | 1 |
| Polavarapu, R | 1 |
| Akahori, H | 1 |
| Pachura, K | 1 |
| Finn, AV | 1 |
| Lipinski, MJ | 1 |
| Pendyala, LK | 1 |
| Torguson, R | 1 |
| Chen, F | 1 |
| Waksman, R | 1 |
| Zheng, H | 1 |
| Gu, J | 1 |
| Ma, L | 1 |
| Yeh, JL | 1 |
| Zhang, R | 1 |
| Qin, C | 1 |
| Wen, L | 1 |
| Cao, Y | 1 |
| Xia, Q | 1 |
| Lu, Y | 1 |
| Li, K | 1 |
| Ghatak, SB | 1 |
| Dhamecha, PS | 1 |
| Bhadada, SV | 1 |
| Panchal, SJ | 1 |
| Klempfner, R | 1 |
| Leor, J | 1 |
| Tenenbaum, A | 1 |
| Fisman, EZ | 1 |
| Goldenberg, I | 1 |
| Stiefelhagen, P | 1 |
| Grant, PJ | 1 |
| Després, JP | 1 |
| Gormsen, J | 1 |
| Laursen, B | 1 |
| Fearnley, GR | 1 |
| Trial | Phase | Enrollment | Study Type | Start Date | Status | ||
|---|---|---|---|---|---|---|---|
| The Effect of Adding Vildagliptin Versus Glimepiride to Metformin on Markers of Inflammation, Thrombosis, and Atherosclerosis in Diabetic Patients With Symptomatic Coronary Artery Diseases[NCT03693560] | Phase 4 | 80 participants (Actual) | Interventional | 2018-10-08 | Completed | ||
| A Pilot Study: Metformin as an Inflammatory Modulating Therapy in Older Adults Without Diabetes[NCT03772964] | Phase 1/Phase 2 | 32 participants (Actual) | Interventional | 2019-01-22 | Completed | ||
| DPP-4 Inhibitors in Patients With Type 2 Diabetes and Acute Myocardial Infarction:Effects on Platelet Function[NCT02377388] | Phase 3 | 74 participants (Actual) | Interventional | 2017-02-07 | Completed | ||
| [information is prepared from clinicaltrials.gov, extracted Sep-2024] | |||||||
Grip strength over time. (NCT03772964)
Timeframe: Day 0 (baseline), 90, and 120 (30 days post metformin exposure)
| Intervention | mmHg (Mean) | ||
|---|---|---|---|
| 0 days | 90 days, compared to 0 days | 120 days, compared to 0 days | |
| 1000mg Exposure | 28.9 | -0.4 | 1.1 |
| 1500mg Exposure | 25.7 | -.2 | .3 |
| 500mg Exposure | 28.2 | -5.3 | .1 |
| Placebo | 25.7 | -.3 | -.6 |
The SPPB is a group of measures that combines the results of the gait speed, chair stand and balance tests. The minimum is zero (worse performance) and the maximum is 12 (best performance). (NCT03772964)
Timeframe: Day 0 (baseline), 90, and 120 (30 days post metformin exposure)
| Intervention | Units on a scale (Mean) | ||
|---|---|---|---|
| 0d | 90d, change from 0d | 120d, change from 0d | |
| 1000mg Exposure | 10.8 | 0.4 | 0.2 |
| 1500mg Exposure | 11.1 | 0.4 | 0.3 |
| 500mg Exposure | 11.2 | -0.3 | 0 |
| Placebo | 10.6 | 1.0 | 0.5 |
Aggregometry area under the curve with the Y-axis being % aggregometry and the X-axis time in minutes. (NCT03772964)
Timeframe: Day 0 (baseline), 30, 60, 90, and 120 (30 days post metformin exposure)
| Intervention | arbitrary units*mins (Mean) | ||||
|---|---|---|---|---|---|
| 0 days | 30 day change from day 0 | 60 days change from day 0 | 90 days change from day 0 | 120 days change from day 0 | |
| 1000mg Exposure | 67 | 8.9 | -23.5 | 2.4 | 1.0 |
| 1500mg Exposure | 196 | -166.7 | -139.8 | -222.5 | -196.7 |
| 500mg Exposure | 56.3 | -34.7 | -28.3 | 1.6 | -49.2 |
| Placebo | 83.3 | -29.6 | -49.4 | -66.6 | -47.6 |
"Bacterial communities using 16S rRNA sequencing in relationship to metformin dosing over time. Species richness or diversity in the sample is measured by Choa1 metric. Chao1 is an estimate of how many species are present in an ecosystem. In general, having more species is considered to be healthier and these values typically range from 100-200 for fecal samples. The Chao1 index over numerous samples across time are explored to understand treatment effects." (NCT03772964)
Timeframe: Day 0 (baseline), 30, 60, 90, and 120 (30 days post metformin exposure)
| Intervention | Index (Mean) | ||||
|---|---|---|---|---|---|
| Day 0 | Day 30 | Day 60 | Day 90 | Day 120 | |
| 1000mg Exposure | 107.6 | 130.7 | 137.9 | 135 | 142.2 |
| 1500mg Exposure | 128.1 | 128.1 | 128.6 | 138.2 | 144.2 |
| 500mg Exposure | 136.5 | 139.9 | 121.4 | 137.8 | 134 |
| Placebo | 141.5 | 144.75 | 134.3 | 152 | 159.2 |
2 reviews available for metformin and Blood Clot
| Article | Year |
|---|---|
Beneficial effects of metformin on haemostasis and vascular function in man.
Topics: Arteriosclerosis; Blood Coagulation; Blood Platelets; Blood Vessels; Cardiovascular Diseases; Diabet | 2003 |
Potential contribution of metformin to the management of cardiovascular disease risk in patients with abdominal obesity, the metabolic syndrome and type 2 diabetes.
Topics: Abdomen; Adipose Tissue; Arteriosclerosis; Blood Glucose; Body Constitution; Cardiovascular Diseases | 2003 |
2 trials available for metformin and Blood Clot
| Article | Year |
|---|---|
Comparative clinical study evaluating the effect of adding Vildagliptin versus Glimepiride to ongoing Metformin therapy on diabetic patients with symptomatic coronary artery disease.
Topics: Adiponectin; Atherosclerosis; Biomarkers; Blood Glucose; Coronary Artery Disease; Diabetes Mellitus, | 2020 |
Effects of a vildagliptin/metformin combination on markers of atherosclerosis, thrombosis, and inflammation in diabetic patients with coronary artery disease.
Topics: Adamantane; Adiponectin; Atherosclerosis; Biomarkers; C-Reactive Protein; Diabetes Mellitus, Type 2; | 2012 |
13 other studies available for metformin and Blood Clot
| Article | Year |
|---|---|
Novel potent antiplatelet thrombotic agent derived from biguanide for ischemic stroke.
Topics: Administration, Oral; Animals; Biguanides; Brain Ischemia; Dose-Response Relationship, Drug; Male; M | 2020 |
Metformin use in patients hospitalized with COVID-19: lower inflammation, oxidative stress, and thrombotic risk markers and better clinical outcomes.
Topics: COVID-19; COVID-19 Drug Treatment; Diabetes Mellitus; Hospitalization; Humans; Hypoglycemic Agents; | 2022 |
Metformin Inhibits Multiple Myeloma Serum-induced Endothelial Cell Thrombosis by Down-Regulating miR-532.
Topics: Cells, Cultured; Endothelial Protein C Receptor; Fibrinolytic Agents; Human Umbilical Vein Endotheli | 2022 |
3D Elastomeric Stent Functionalized with Antioxidative and Perivascular Tissue Regenerative Activities Ameliorated PVT Deprivation-Induced Vein Graft Failure.
Topics: Animals; Antioxidants; Hyperplasia; Metformin; Reactive Oxygen Species; Stents; Thrombosis | 2023 |
Metformin and SARS-CoV-2: mechanistic lessons on air pollution to weather the cytokine/thrombotic storm in COVID-19.
Topics: Aged; Betacoronavirus; Calcium Release Activated Calcium Channels; Coronavirus Infections; COVID-19; | 2020 |
Metformin Targets Mitochondrial Electron Transport to Reduce Air-Pollution-Induced Thrombosis.
Topics: Air Pollution; Animals; Cell Line; Cytokines; Electron Transport; Humans; Interleukin-6; Lung Diseas | 2019 |
Metformin impairs endothelialization after placement of newer generation drug eluting stents.
Topics: Angioplasty, Balloon; Animals; Disease Models, Animal; Drug-Eluting Stents; Endothelium, Vascular; E | 2013 |
Stent thrombosis is not increased following percutaneous coronary intervention in patients with non-insulin dependent diabetes mellitus taking metformin.
Topics: Aged; Diabetes Mellitus, Type 2; Drug-Eluting Stents; Female; Humans; Male; Metformin; Middle Aged; | 2014 |
Metformin Uniquely Prevents Thrombosis by Inhibiting Platelet Activation and mtDNA Release.
Topics: Animals; Blood Platelets; Diabetes Mellitus, Type 2; DNA, Mitochondrial; Electron Transport Complex | 2016 |
Investigation of the potential effects of metformin on atherothrombotic risk factors in hyperlipidemic rats.
Topics: Animals; Antioxidants; Aorta; Atherosclerosis; Blood Coagulation; Body Weight; Carotid Arteries; Cho | 2011 |
[Stroke is not equal to stroke. Keep track of the causes].
Topics: Adult; Antihypertensive Agents; Aspirin; Carotid Artery, Common; Carotid Artery, External; Carotid S | 2003 |
Studies on pharmacological enhancement of blood fibrinolytic activity.
Topics: Aged; Arteriosclerosis; Clofibrate; Female; Fibrinogen; Fibrinolysis; Fibrinolytic Agents; Humans; I | 1970 |
[Physiological and pharmacological aspects of fibrinolysis].
Topics: Adrenal Cortex Hormones; Anabolic Agents; Arteriosclerosis Obliterans; Biguanides; Blood Coagulation | 1971 |